Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.

被引：0
|
作者：
Vardell, Victoria
Tantravahi, Srinivas Kiran
机构：
[1] Univ Utah, Dept Hematol & Hematol Malignancies, Salt Lake City, UT USA
[2] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11187
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Yoshihiro Umezawa
    Koji Sasaki
    International Journal of Hematology, 2023, 117 : 24 - 29
  • [22] Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Jabbour, Elias J.
    Kantarjian, Hagop
    Eliasson, Lina
    Cornelison, A. Megan
    Marin, David
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (07) : 687 - 691
  • [23] Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Gong, Zimu
    Zheng, Lan
    Tang, Zhenya
    Chen, Zi
    Wang, Wei
    Bai, Shi
    Tang, Guilin
    Medeiros, L. Jeffrey
    Hu, Shimin
    ANNALS OF HEMATOLOGY, 2017, 96 (03) : 501 - 504
  • [24] Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Huang, Xuelin
    Cortes, Jorge
    Kantarjian, Hagop
    CANCER, 2012, 118 (12) : 3123 - 3127
  • [25] Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Chen, Z.
    Shao, C.
    Wang, W.
    Zuo, Z.
    Mou, X.
    Hu, S. J.
    DiGiuseppe, J. A.
    Zu, Y.
    Medeiros, L. J.
    Hu, S.
    LEUKEMIA, 2017, 31 (03) : 585 - 592
  • [26] Cytogenetic Landscape and Impact in Blast Phase of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy
    Chen, Zi
    Wang, Wei
    Medeiros, L. Jeffrey
    Hu, Shimin
    MODERN PATHOLOGY, 2017, 30 : 342A - 342A
  • [27] Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Z Chen
    C Shao
    W Wang
    Z Zuo
    X Mou
    S J Hu
    J A DiGiuseppe
    Y Zu
    L J Medeiros
    S Hu
    Leukemia, 2017, 31 : 585 - 592
  • [28] Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Zimu Gong
    Lan Zheng
    Zhenya Tang
    Zi Chen
    Wei Wang
    Shi Bai
    Guilin Tang
    L. Jeffrey Medeiros
    Shimin Hu
    Annals of Hematology, 2017, 96 : 501 - 504
  • [29] Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia
    Radich, Jerald P.
    Mauro, Michael J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 577 - +
  • [30] Caring for Patients with Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitor (TKI) Therapy in an Era of Evolving Treatment Goals
    Nodzon, Lisa A.
    Tinsley, Sara M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S224 - S225
12345